ArticleFrontiers in oncology2026
Nanopore and EPIC array profiling unmask an atypical non-midline H3 K27-altered glioma: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of Diffuse Midline Glioma, H3K27-altered, arising in a non-midline fronto-temporo-insular location in a 48-year-old adult, initially mimicking Glioblastoma, IDH-wildtype, based on radiology and histopathology. Integrated molecular diagnostics, including genome-wide DNA methylation profiling and Sanger sequencing, confirmed an H3.3 K27M mutation, while Nanopore-based methylation profiling provided a rapid and fully concordant classification, demonstrating the feasibility of real-time epigenomic diagnostics in clinical practice. H3K27M-mutant diffuse non-midline gliomas (DNMG) are extremely rare, with only ~39 cases reported in the literature, most commonly involving the temporal lobe and associated with poor prognosis. Our case highlights that DNMGs can present in adults and in previously unreported hemispheric locations, underscoring the importance of integrated molecular testing not only for accurate diagnosis but also to guide patient management and enable enrollment in potential targeted therapies. Molecular profiling thus represents a critical tool for personalized treatment planning and prognostic assessment in these uncommon gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.